NBIX vs QGEN
Neurocrine Biosciences, Inc. and Qiagen N.v., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | NBIX | QGEN |
|---|---|---|
| Revenue | $2.9B | $2.1B |
| Net income | $478.6M | $424.9M |
| Gross margin | 98.2% | 62.2% |
| Net margin | 16.7% | 20.3% |
| Return on equity | 16.4% | 11.6% |
| Diluted EPS | $4.67 | $1.94 |
| Dividend / share | — | $0.25 |
| Payout ratio | — | 12.8% |
| Free cash flow | $748.7M | $453.3M |
| Equity | $3.3B | $3.8B |
| Net debt / equity | — | 0.22× |
| Current ratio | 3.39× | 3.90× |
| Revenue CAGR 5y | 22.3% | 2.2% |
| Profit CAGR 5y | 3.3% | 3.4% |
NBIX bills 1.4× the revenue of QGEN, and QGEN keeps more of each dollar of revenue as profit (20.3% against 16.7%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | NBIX | QGEN |
|---|---|---|
| FY2025 | $2.9B | $2.1B |
| FY2024 | $2.4B | $2.0B |
| FY2023 | $1.9B | $2.0B |
| FY2022 | $1.5B | $2.1B |
| FY2021 | $1.1B | $2.3B |
| FY2020 | $1.0B | $1.9B |
| FY2019 | $788.1M | $1.5B |
| FY2018 | $451.2M | $1.5B |
| FY2017 | $161.6M | $1.4B |
| FY2016 | $15.0M | $1.3B |
Net income by year
Bottom line
| Fiscal year | NBIX | QGEN |
|---|---|---|
| FY2025 | $478.6M | $424.9M |
| FY2024 | $341.3M | $83.6M |
| FY2023 | $249.7M | $341.3M |
| FY2022 | $154.5M | $423.2M |
| FY2021 | $89.6M | $512.6M |
| FY2020 | $407.3M | $359.2M |
| FY2019 | $37.0M | $-41.5M |
| FY2018 | $21.1M | $190.4M |
| FY2017 | $-142.5M | $40.4M |
| FY2016 | $-141.1M | $80.4M |
Advertisement
AdSense · Rectangle 336×280
More in this industry